Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs Silhouette MD

Henry Meds
Graded #46

Higher grade

vs+7.8999999999999915
Silhouette MD
Graded #129

Lower grade

The verdict

Henry Meds takes it — 77.3/100 to 69.4/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSilhouette MD +2
72
74
Dose & formulationHenry Meds +5
80
75
Clinical oversightHenry Meds +3
80
77
Labs & monitoringHenry Meds +24
78
54
FulfillmentHenry Meds +11
78
67
Contract termsHenry Meds +23
78
55
Henry Meds · left barSilhouette MD · right bar

The numbers

MetricHenry MedsSilhouette MD
WeighScore77.3/10069.4/100
GradeC+C
Scorecard rank#46#129
Semaglutide$249/mo$149/mo (compounded)
Tirzepatide$349/mo$299/mo (compounded)
CoverageMulti-stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Henry Meds

Graded #46 · C+

Strengths

  • Simple flat-fee model
  • Established brand
  • Both molecules

Where it loses points

  • Higher pricing than newer entrants
  • Compounded only
Silhouette MD

Graded #129 · C

Strengths

  • Compounded semaglutide and tirzepatide in both injectable and oral formulations
  • Concierge-level support — monitoring, expert guidance, and check-ins included on every plan
  • Transparent, published pricing starting at $149/mo for semaglutide injection
  • Prescriptions issued and fulfilled by licensed clinical partner OpenLoop Health

Where it loses points

  • Tirzepatide ($299/mo) and oral options ($263–$325/mo) priced above many compounded competitors
  • State availability not published
  • Newer brand with limited independent review history
  • Medications are compounded, not FDA-approved brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard